# INTERVIEW: SkinBioTherapeutics PLC Increased Attention

- Link: https://www.directorstalkinterviews.com/interview-skinbiotherapeutics-plc-increased-attention/412737445
- Published: 2017-10-04T08:49:16+01:00
- Author: Giles Arbor

**SkinBioTherapeutics PLC** (LON:SBTX) CEO Dr. Catherine O’Neill talks to DirectorsTalk
about passing 3rd party cellular toxicity tests. Catherine explains what was involved
and what this means for the company, key points that investors should take from 
the scientific update and what investors should expect in terms of news flow over
the coming months.

SkinBioTherapeutics is a life science company focused on skin health. The Company’s
proprietary platform technology, SkinBiotix®, is based upon discoveries made by 
CEO Dr. Catherine O’Neill and Professor Andrew McBain.

The company’ platform applies research discoveries made on the activities of lysates
derived from probiotic bacteria when applied to the skin. The Company has shown 
that the SkinBiotix® platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of principle studies have
shown that the SkinBiotix® platform has beneficial attributes applicable to each
of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University
of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun
out of the University of Manchester in March 2016 and was funded by OptiBiotix.

Share on: